Treatment of allergic rhinitis

American Journal of Medicine

Volumn 113, Issue 9 SUPPL. 1, 2002, Pages 17-24

  Rosenwasser, Lanny J ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ALLERGEN; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; EYE DROPS; FEXOFENADINE; LEVOCABASTINE; LORATADINE; STEROID; TERFENADINE;

ALLERGIC RHINITIS; ASTHMA; AVOIDANCE BEHAVIOR; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG INDICATION; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; HEART ARRHYTHMIA; HUMAN; IMMUNOTHERAPY; MEDICAL RESEARCH; MONOTHERAPY; NASAL PRURITUS; NOSE CONGESTION; ORGANIZATION; PATHOGENESIS; PATIENT EDUCATION; PHYSICAL EXAMINATION; PRICK TEST; PRIORITY JOURNAL; REVIEW; RHINITIS; RHINORRHEA; SEASON; SEDATION; SNEEZING;

EID: 0037122407     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(02)01433-x     Document Type: Review

References (41)

1. Dykewicz M.S., Fineman S., Skoner D.P., et al. Diagnosis and management of rhinitis complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology . Ann Allergy Asthma Immunol. 81:(Pt 2):1998;478-518.
2. Kay G.G. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 105:2000;S622-S627.
3. Stempel D.A., Woolf R. The cost of treating allergic rhinitis. Curr Allergy Asthma Rep. 2:2002;223-230.
4. Hayden M.L. Allergic rhinitis a growing primary care challenge . J Am Acad Nurse Pract. 13:2001;545-554.
5. Ceuppens J. Western lifestyle, local defenses and the rising incidence of allergic rhinitis. Acta Otorhinolaryngol Belg. 54:2000;391-395.
6. American Academy of Allergy, Asthma and Immunology. The Allergy Report. Available at: www.theallergyreport.org/reportindex.html. Accessed June 24, 2002.
7. Settipane R.A. Complications of allergic rhinitis. Allergy Asthma Proc. 20:1999;209-213.
8. Skoner D.P. Allergic rhinitis definition, epidemiology, pathophysiology, detection, and diagnosis . J Allergy Clin Immunol. 8:2001;S2-S8.
9. Sly R.M. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol. 82:1999;233-252.
10. Greisner W.A. III, Settipane R.J., Settipane G.A. The course of asthma parallels that of allergic rhinitis a 23-year follow-up study of college students . Allergy Asthma Proc. 21:2000;371-375.
11. Bellanti J.A., Wallerstedt D.B. Allergic rhinitis update epidemiology and natural history . Allergy Asthma Proc. 21:2000;367-370.
12. Pearlman D.S. Pathophysiology of the inflammatory response. J Allergy Clin Immunol. 104:1999;S132-S137.
13. Stirling R.G., Chung K.F. Future treatments of allergic diseases and asthma. Br Med Bull. 56:2000;1037-1053.
14. Fokkens W.J., Vinke J.G., KleinJan A. Local IgE production in the nasal mucosa a review . Am J Rhinol. 14:2000;299-303.
15. Leung D.Y. Molecular basis of allergic diseases. Mol Genet Metab. 63:1998;157-167.
16. Benson M., Strannegard I.L., Wennergren G., Strannegard O. Low levels of interferon-gamma in nasal fluid accompany raised levels of T-helper 2 cytokines in children with ongoing allergic rhinitis. Pediatr Allergy Immunol. 11:2000;20-28.
17. Pawankar R., Yamagishi S., Yagi T. Revisiting the roles of mast cells in allergic rhinitis and its relation to local IgE synthesis. Am J Rhinol. 14:2000;309-317.
18. Terada N., Hamano N., Hohki G., et al. The potential role of interleukin-13 in eosinophilic inflammation in nasal mucosa. Allergy. 53:1998;690-697.
19. Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 108:2001;S147-S336.
20. Traikova N.I., Dzhambazov K.B., Tatarev G.P. Optimisation of the technique of computed tomographic imaging of paranasal sinuses. Folia Med (Plovdiv). 43:2001;32-36.
21. Clarinex [prescribing information]. Kenilworth, NJ: Schering Corporation. Available at: Clarinex.com. Accessed June 28, 2002.
22. Claritin [prescribing information]. Kenilworth, NJ: Schering Corporation; updated September 2000. Available at: http://www.claritin.com/pi/claritin.html. Accessed June 28, 2002.
23. Zyrtec [prescribing information]. New York: Pfizer Laboratories; updated 2000. Available at: http://www.zyrtec.com/index.asp?pageid=4&subid=100&contentid=100. Accessed June 28, 2002.
24. Allegra [prescribing information]. Kansas City, MO: Aventis Pharmaceuticals. Updated November 2000.
25. Warren R, Simpson H, Hilchie J, Cimbura G, Lucas D, Bennett R. Drugs detected in fatally injured drivers in the province of Ontario. In: Goldberg L, ed. Alcohol, Drugs, and Traffic Safety, 1st ed. Stockholm, Sweden: Almquist and Weksell, 1981:203-217.
26. Day J. Pros and cons of the use of antihistamines in managing allergic rhinitis. J Allergy Clin Immunol. 103:1999;S395-S399.
27. 1-receptor antagonists. Allergy. 55:(suppl 64):2000;17-27.
28. van Cauwenberge P., Juniper E.F. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 30:2000;891-899.
29. Ciprandi G., Consentino C., Milanese M., Mondino C., Canonica G.W. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy. 56:2001;1068-1070.
30. Horak F., Stubner P., Zieglmayer R., et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol. 125:2001;73-79.
31. Horak F, Stubner UP, Zieglmayer R, Harris AG: Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002;109:965-961.
32. Salmun L.M. Antihistamines in late-phase clinical develop-ment for allergic disease. Expert Opin Investig Drugs. 11:2002;259-273.
33. Wilson A.M., Orr L.C., Coutie W.J., Sims E.J., Lipworth B.J. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy. 32:2002;126-132.
34. Golden S.J., Craig T.J. Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. J Am Osteopath Assoc. 99:(suppl):1999;S7-S12.
35. 1 receptor antagonists in allergic rhinitis systematic review of randomised controlled trials . BMJ. 317:1998;1624-1629.
36. Juniper E.F., Guyatt G.H., Ferrie P.J., Griffith L.E. First-line treatment of seasonal (ragweed) rhinoconjunctivitis. CMAJ. 156:1997;1123-1131.
37. Malone D.C., Lawson K.A., Smith D.H., et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol. 99:1997;22-27.
38. Storms W.W. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol. 88:(suppl 1):2002;30-35.
39. Rice K.D., Tanaka R.D., Katz B.A., Numerof R.P., Moore W.R. Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 4:1998;381-396.
40. Albert D.H., Malo P.E., Tapang P., et al. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 284:1998;83-88.
41. Lee W.C., Morgan D.W., Marriott J.F. Are prostaglandins major mediators in perennial allergic rhinitis? Rhinology. 34:1996;130-135.